MA35932B1 - Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine - Google Patents
Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitineInfo
- Publication number
- MA35932B1 MA35932B1 MA37338A MA37338A MA35932B1 MA 35932 B1 MA35932 B1 MA 35932B1 MA 37338 A MA37338 A MA 37338A MA 37338 A MA37338 A MA 37338A MA 35932 B1 MA35932 B1 MA 35932B1
- Authority
- MA
- Morocco
- Prior art keywords
- activating enzyme
- chemical entities
- ubiquitin activating
- pyrazolopyrimidinyl
- inhibitors
- Prior art date
Links
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 title abstract 2
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 title abstract 2
- -1 Pyrazolopyrimidinyl Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600070P | 2012-02-17 | 2012-02-17 | |
| PCT/US2013/026113 WO2013123169A1 (en) | 2012-02-17 | 2013-02-14 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35932B1 true MA35932B1 (fr) | 2014-12-01 |
Family
ID=48982730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37338A MA35932B1 (fr) | 2012-02-17 | 2014-09-10 | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9290500B2 (OSRAM) |
| EP (3) | EP3173413B1 (OSRAM) |
| JP (1) | JP6122877B2 (OSRAM) |
| KR (1) | KR20140123104A (OSRAM) |
| CN (1) | CN104136399B (OSRAM) |
| AR (1) | AR092797A1 (OSRAM) |
| BR (1) | BR112014020365B1 (OSRAM) |
| CA (1) | CA2864672C (OSRAM) |
| CL (1) | CL2014002181A1 (OSRAM) |
| CO (1) | CO7071135A2 (OSRAM) |
| CR (1) | CR20140380A (OSRAM) |
| DO (1) | DOP2014000187A (OSRAM) |
| EA (1) | EA035020B1 (OSRAM) |
| EC (1) | ECSP14019113A (OSRAM) |
| ES (1) | ES2739150T3 (OSRAM) |
| GE (1) | GEP201706687B (OSRAM) |
| HK (1) | HK1201817A1 (OSRAM) |
| IL (1) | IL234016A0 (OSRAM) |
| MA (1) | MA35932B1 (OSRAM) |
| MX (1) | MX352963B (OSRAM) |
| NZ (1) | NZ628969A (OSRAM) |
| PE (1) | PE20142244A1 (OSRAM) |
| PH (1) | PH12014501832A1 (OSRAM) |
| SG (2) | SG10201606581RA (OSRAM) |
| TN (1) | TN2014000351A1 (OSRAM) |
| TW (1) | TWI593688B (OSRAM) |
| UA (1) | UA116534C2 (OSRAM) |
| UY (1) | UY34629A (OSRAM) |
| WO (1) | WO2013123169A1 (OSRAM) |
| ZA (1) | ZA201406103B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| KR20140123104A (ko) | 2012-02-17 | 2014-10-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제 |
| WO2014022744A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 |
| EP3016934B1 (en) | 2013-07-02 | 2018-01-10 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| JP6603712B2 (ja) | 2014-07-01 | 2019-11-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物 |
| WO2016069393A1 (en) | 2014-10-29 | 2016-05-06 | Millennium Pharmaceuticals, Inc. | Administration of ubiquitin-activating enzyme inhibitor and radiation |
| US20180133221A1 (en) | 2014-10-29 | 2018-05-17 | Millennium Pharmaceuticals, Inc. | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents |
| AU2019370200B2 (en) | 2018-10-30 | 2024-12-19 | Kronos Bio, Inc. | Compounds, compositions, and methods for modulating CDK9 activity |
| WO2023021498A1 (en) * | 2021-08-16 | 2023-02-23 | Moya Bio Ltd. | Fused azole and furan based nucleoside analogs and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023901A1 (en) | 2002-02-28 | 2004-02-05 | Cook Phillip D. | Nucleoside 5'-monophosphate mimics and their prodrugs |
| JP2006501260A (ja) | 2002-09-04 | 2006-01-12 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| US7067661B2 (en) | 2002-09-04 | 2006-06-27 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| EP1758873A1 (en) | 2004-06-22 | 2007-03-07 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| WO2007044426A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| DK1989206T3 (da) | 2006-02-02 | 2012-10-08 | Millennium Pharm Inc | E1-aktiveringsenzymhæmmere |
| US8147618B2 (en) * | 2006-02-28 | 2012-04-03 | Lam Research Ag | Device and method for liquid treating disc-like articles |
| MY157177A (en) | 2006-08-08 | 2016-05-13 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| ES2757928T3 (es) | 2007-08-02 | 2020-04-30 | Millennium Pharm Inc | Proceso para la síntesis de inhibidores de enzimas activadoras E1 |
| WO2009082691A1 (en) | 2007-12-21 | 2009-07-02 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| NZ596470A (en) | 2009-05-14 | 2014-04-30 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate |
| WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| CA2846231C (en) | 2011-08-24 | 2017-06-20 | Millennium Pharmaceuticals, Inc. | Inhibitors of nedd8-activating enzyme |
| KR20140123104A (ko) | 2012-02-17 | 2014-10-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제 |
| WO2014022744A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 |
| EP3016934B1 (en) | 2013-07-02 | 2018-01-10 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| JP6603712B2 (ja) | 2014-07-01 | 2019-11-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物 |
-
2013
- 2013-02-14 KR KR1020147025556A patent/KR20140123104A/ko not_active Ceased
- 2013-02-14 BR BR112014020365-2A patent/BR112014020365B1/pt active IP Right Grant
- 2013-02-14 EA EA201400831A patent/EA035020B1/ru not_active IP Right Cessation
- 2013-02-14 CA CA2864672A patent/CA2864672C/en active Active
- 2013-02-14 SG SG10201606581RA patent/SG10201606581RA/en unknown
- 2013-02-14 EP EP16205139.5A patent/EP3173413B1/en active Active
- 2013-02-14 SG SG11201404757WA patent/SG11201404757WA/en unknown
- 2013-02-14 GE GEAP201313560A patent/GEP201706687B/en unknown
- 2013-02-14 CN CN201380009784.8A patent/CN104136399B/zh active Active
- 2013-02-14 NZ NZ628969A patent/NZ628969A/en not_active IP Right Cessation
- 2013-02-14 MX MX2014009944A patent/MX352963B/es active IP Right Grant
- 2013-02-14 UA UAA201409297A patent/UA116534C2/uk unknown
- 2013-02-14 HK HK15102227.4A patent/HK1201817A1/xx unknown
- 2013-02-14 WO PCT/US2013/026113 patent/WO2013123169A1/en active Application Filing
- 2013-02-14 PE PE2014001278A patent/PE20142244A1/es active IP Right Grant
- 2013-02-14 EP EP19170607.6A patent/EP3536692B1/en active Active
- 2013-02-14 ES ES16205139T patent/ES2739150T3/es active Active
- 2013-02-14 EP EP13748707.0A patent/EP2814791A4/en not_active Withdrawn
- 2013-02-14 JP JP2014557765A patent/JP6122877B2/ja active Active
- 2013-02-14 US US13/767,314 patent/US9290500B2/en active Active
- 2013-02-15 AR ARP130100480A patent/AR092797A1/es unknown
- 2013-02-15 UY UY0001034629A patent/UY34629A/es not_active Application Discontinuation
- 2013-02-18 TW TW102105676A patent/TWI593688B/zh not_active IP Right Cessation
-
2014
- 2014-08-07 IL IL234016A patent/IL234016A0/en unknown
- 2014-08-11 TN TNP2014000351A patent/TN2014000351A1/fr unknown
- 2014-08-12 CR CR20140380A patent/CR20140380A/es unknown
- 2014-08-13 PH PH12014501832A patent/PH12014501832A1/en unknown
- 2014-08-14 CL CL2014002181A patent/CL2014002181A1/es unknown
- 2014-08-15 DO DO2014000187A patent/DOP2014000187A/es unknown
- 2014-08-20 ZA ZA2014/06103A patent/ZA201406103B/en unknown
- 2014-09-10 MA MA37338A patent/MA35932B1/fr unknown
- 2014-09-16 CO CO14205517A patent/CO7071135A2/es unknown
- 2014-09-17 EC ECIEPI201419113A patent/ECSP14019113A/es unknown
-
2016
- 2016-02-19 US US15/048,007 patent/US9663525B2/en active Active
-
2017
- 2017-04-17 US US15/488,800 patent/US9796725B2/en active Active
- 2017-09-08 US US15/699,818 patent/US10202389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35932B1 (fr) | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA45920A (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
| MX2014000536A (es) | Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa. | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| MA33032B1 (fr) | Pyrimidines condensees | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| EA201201665A1 (ru) | Новые соединения | |
| MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
| MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
| MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
| MA35661B1 (fr) | Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| TN2012000534A1 (en) | Pyrazole compounds as sigma receptor inhibitors | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA39186A1 (fr) | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose | |
| MA32997B1 (fr) | Macrolide anti-inflammatoire | |
| MY152040A (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments | |
| MX2010007892A (es) | Imidazopiridazinas como inhibidores de par1, su produccion y uso como medicamentos. | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
| MA38206B1 (fr) | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
| MA35814B1 (fr) | Thiazoles à substitution 2-(chroman-6-yloxy) et leur utilisation comme produits pharmaceutiques | |
| MA38207A2 (fr) | Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées |